a hepatic metabolite of cyclophosphamide and ifosfamide. 3 The incidence of HC is related to the amount of drug and the cumulative doses. 4 Adotrastuzumab emtansine (T-DM1) is an antibodydrug complex locked to HER2. This complex use its mechanism that can conjugate for HER2 and bind to tubulin disrupt the intracellular microtubule network, leading to cell cycle arrest and apoptosis for treatment of breast cancer. To the best of our knowledge, ado-trastuzumab emtansine-induced HC has never been reported. According to clinical trials experience, common adverse reactions and toxicity are thrombocytopenia, anemia, urinary tract infection, hepatotoxicity, and cardiotoxicity. 5 The precise pathogenesis of T-DM1-induced HC is not understood. The time sequence between the administrations of T-DM1 and onset of HC in our patient highly suggested the association. Although HC is common in some high-dose chemotherapy, it is never reported in T-DM1. Health care professionals are advised to be aware of early presentations of these syndromes. Timely recognition of a drug adverse reaction and early discontinuation of the offending agents and treatment may have important health consequences.